<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394663</url>
  </required_header>
  <id_info>
    <org_study_id>RP019</org_study_id>
    <nct_id>NCT04394663</nct_id>
  </id_info>
  <brief_title>High Dose Oral Omeprazole in High Risk UGIB</brief_title>
  <official_title>High Dose Oral Omeprazole Versus Standard Continuous Intravenous Pantoprazole in Patient With Peptic Ulcer Bleeding and Undergo Successful Therapeutic Endoscopy; Non-inferiority Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Chulalongkorn Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Chulalongkorn Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peptic ulcer bleeding is the most common etiology in upper gastrointestinal bleeding all over
      the world. After endoscopic treatment, proton pump inhibitor (PPI) is recommended to prevent
      re-bleeding. Intravenous PPI is recommended as a standard treatment.In the past, there were
      many trials showing the efficacy of high-dose oral PPI after endoscopic hemostasis but most
      were industrial sponsor which assessing an expensive PPI. Moreover, the number of patients in
      those studies were insufficient to confirm a non-inferiority outcome in term of rebleeding by
      using oral PPI. This study will evaluate a high-dose, local-made PPI (omeprazole) in peptic
      ulcer treatment after successful endoscopic hemostasis compared to standard IV PPI continuous
      drip.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients with successful endoscopic hemostasis in peptic ulcer bleeding were equally randomized to either high-dose oral PPI or standard IV PPI for 3 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The outcomes assessor will not know the assigned treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peptic ulcer rebleeding within 30 days</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>GI Bleeding</condition>
  <arm_group>
    <arm_group_label>High-dose oral PPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omeprazole 80 mg/day (40 mg twice a day) per oral route for 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard IV PPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pantoprazole 8 mg/hour IV continuous drip for 72 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose oral omeprazole</intervention_name>
    <description>Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.</description>
    <arm_group_label>High-dose oral PPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard IV PPI</intervention_name>
    <description>Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization</description>
    <arm_group_label>Standard IV PPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with peptic ulcer bleeding and endoscopic finding show ulcer with Forrest
             classification Ia (spurting haemorrhage), IIa (oozing haemorrhage), Ib (non-bleeding
             visible vessel)

          -  Age &gt; 18 years old

        Exclusion Criteria:

          -  Deny to participate

          -  Pregnancy or lactation

          -  Low risk peptic ulcer bleeding including clean base ulcer, flat pigmented spot

          -  Non-peptic ulcer bleeding eg. erosive gastritis/duodenitis, Mallory Weiss tear,
             esophageal/gastric/duodenal varices, vascular lesions (eg. Dieulafoy) , malignant
             ulcer

          -  Bleeding tendency

          -  Terminal stage of cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rapat Pittayanon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Chulalongkorn Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rapat Pittayanon, MD</last_name>
    <phone>66804224999</phone>
    <email>rapat125@gmail.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Chulalongkorn Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Rapat Pittayanon</investigator_full_name>
    <investigator_title>Principle investigator, Gastrointestinal Unit</investigator_title>
  </responsible_party>
  <keyword>oral proton pump inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

